Clinical trials: Pediatric Patients With Solid Tumors
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well selumetinib sulfate works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with MAPK pathway activation mutations that have spread to…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm
- Trial name
- NCT03213691
- Testing
- Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate
- Where
- 110 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma, Rhabdomyosarcoma
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
This is a Phase I, open-label, dose-escalation trial of JX-594 (Pexa-Vec) in pediatric patients with advanced/metastatic, unresectable solid tumors refractory to standard therapy and/or the patient does not tolerate standard…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Wilm's Tumor
- Trial name
- NCT01169584
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Jennerex Biotherapeutics
Solid Tumors, Hematological Tumor
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
The goal of this clinical trial is to evaluate the efficacy and safety of romiplostim N01 in treating chemotherapy-induced thrombocytopenia (CIT) in children and adolescents/young adults (CAYA; aged 6-24 years) with hematologic…
- Conditions
- Solid Tumors, Hematological Tumor, Children, Adolescent
- Trial name
- NCT07043894
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Brain Tumors, Central Nervous System Tumors
Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma
RATIONALE: Electroacupuncture may help to reduce or prevent delayed nausea and vomiting in patients treated with chemotherapy. PURPOSE: This randomized clinical trial is studying the effectiveness of electroacupuncture in…
- Conditions
- Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00040911
- Testing
- electroacupuncture therapy, quality-of-life assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Children's Oncology Group
Recurrent Solid Tumor, Refractory Solid Tumor
ODSH + ICE Chemotherapy in Pediatric Solid Tumors
This study will be with pediatric patients who have refractory/recurrent solid tumors. They will receive standard chemotherapy (ICE) and we are investigating if the addition of a new drug, ODSH, will help to increase the time of…
- Conditions
- Recurrent Solid Tumor, Refractory Solid Tumor, Sarcoma, Wilms' Tumor
- Trial name
- NCT02164097
- Testing
- ODSH
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- New York Medical College
Stage IV Breast Cancer, Stage IV Pancreatic Cancer
Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
This study evaluates the change of quality of life, treatment decision and utilization of health care depending on the use of palliative care in advanced cancer patients by a prospective cohort study.
- Conditions
- Stage IV Breast Cancer, Stage IV Pancreatic Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer
- Trial name
- NCT03222258
- Testing
- Early palliative care, Routine hospice care
- Where
- 15 sites in South Korea
- Volunteers
- 444 people
- Sponsor
- Seoul National University Hospital
Solid Tumors
A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)
The main objectives of this trial are to determine the recommended dose of ridaforolimus for pediatric participants with advanced solid tumors by measuring the number of participants experiencing dose-limiting toxicities (DLTs)…
- Trial name
- NCT01431534
- Testing
- Ridaforolimus
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well samotolisib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that have spread to other places in the…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Malignant Glioma
- Trial name
- NCT03213678
- Testing
- Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography
- Where
- 127 sites in United States, Puerto Rico
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Brain Stem Neoplasms, Glioma
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Background: IMC-A12 is an experimental substance designed to inhibit a protein called Type I Insulin-Like Growth Factor Receptor (IGF-1R), which can be found on cancer cells and can promote cancer growth.
- Conditions
- Brain Stem Neoplasms, Glioma, Pinealoma
- Trial name
- NCT01182883
- Testing
- IMC-A12, Temsirolimus
- Sponsor
- National Cancer Institute (NCI)
Relapsed Solid Tumor, Refractory Solid Tumor
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Phase 1: To confirm the safety and anticipated recommended phase 2 dose (RP2D) of REGN2810 (cemiplimab) for children with recurrent or refractory solid or Central Nervous System (CNS) tumors To characterize the pharmacokinetics…
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor
- Trial name
- NCT03690869
- Testing
- cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated
- Where
- 20 sites in United States
- Volunteers
- 57 people
- Sponsor
- Regeneron Pharmaceuticals
Neuroblastoma, Rhabdomyosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors
- Trial name
- NCT06625190
- Testing
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Florida
Low-grade Glioma, Advanced Solid Tumor
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors.
- Trial name
- FIREFLY-1 (NCT04775485)
- Testing
- Tovorafenib
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 141 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
ABT-751 in Treating Young Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00036959
- Testing
- ABT-751
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pediatric Solid Tumor, Unspecified, Protocol Specific
Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children
The purpose is to evaluate the efficacy of ondansetron oral soluble film plus dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) with MEC/HEC chemotherapy in children with solid tumor.
- Trial name
- NCT06208917
- Testing
- Ondansetron (Oral soluble film OR injections) ,Dexamethasone
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Yizhuo Zhang
Neoplasm Metastasis
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies.
- Trial name
- NCT02677116
- Testing
- Olaratumab, Doxorubicin, Vincristine
- Where
- 21 sites in United States, Japan
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Brain and Central Nervous System Tumors, Lymphoma
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00004212
- Testing
- filgrastim, exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
Depression, Neurotoxicity
Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression
RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease…
- Conditions
- Depression, Neurotoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00069927
- Testing
- Adderall-XR®, Concerta®
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of South Florida
Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of flavopiridol in treating children who have relapsed or refractory solid…
- Conditions
- Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma
- Trial name
- NCT00012181
- Testing
- alvocidib, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma
The goal of this clinical research study is to learn how long it takes for certain types of transplanted stem cells to produce new blood cells. The safety of this treatment will also be studied.
- Trial name
- NCT00539500
- Testing
- Carboplatin, Etoposide, Melphalan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Refractory Solid Tumor
Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
The purpose of this clinical research study is to establish the maximum tolerated dose and recommended Phase II dose of Erbitux™ in combination with Irinotecan in pediatric and adolescent patients with refractory solid tumors.
- Trial name
- NCT00110357
- Testing
- Cetuximab + Irinotecan
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company